Ferroptosis is characterized by the accumulation of lipid peroxides to lethal levels, distinct from apoptosis or necrosis. The dual modulation of cellular stress pathways by Nelfinavir appears to be central to tipping the balance toward ferroptotic death. Crucially, this investigation demonstrates that Nelfinavir downregulates the GPX4/GSH system, a canonical antioxidant pathway that protects cells from lipid peroxidation. GPX4 (glutathione peroxidase 4) acts as a gatekeeper against ferroptosis by detoxifying lipid hydroperoxides using the reducing power of glutathione (GSH). The pharmacological suppression of this enzyme complex sensitizes malignant cells to oxidative damage.

Simultaneously, researchers observed an upregulation of the NRF2/HO-1 axis in response to Nelfinavir-induced ER stress. NRF2 (nuclear factor erythroid 2-related factor 2) is a master regulator of cellular antioxidant responses, typically activated to counterbalance oxidative insults. Its target gene, HO-1 (heme oxygenase-1), catalyzes heme degradation with cytoprotective outcomes. However, paradoxically, the NRF2/HO-1 pathway’s induction here fails to confer sufficient protection against the oxidative stress, suggesting a complex interplay where protective signaling is overridden, steering cells toward ferroptosis.

Mitochondrial impairment emerged as a critical downstream event following ER stress induction by Nelfinavir. The mitochondria, as cellular powerhouses, are also central regulators of redox homeostasis and metabolic control. The study identified marked disruptions in mitochondrial membrane potential and respiration efficiency, further exacerbating reactive oxygen species (ROS) accumulation. This mitochondrial distress contributes decisively to cellular demise by fostering an environment conducive to lipid peroxidation and ferroptosis execution.

This research carries momentous implications because hepatocellular carcinoma remains a global health challenge, with limited effective therapies for advanced stages. Targeting ferroptosis represents a cutting-edge strategy, exploiting cancer cells’ vulnerabilities to oxidative stress. By repositioning Nelfinavir, an FDA-approved protease inhibitor traditionally used in HIV treatment, as a ferroptosis inducer in liver cancer cells, this study offers a promising translational framework that could expedite clinical applications.

The elegant experimental approach involved detailed molecular analyses and multiple cellular assays to validate the impact of Nelfinavir on ER stress markers, antioxidant system components, and mitochondrial function. Protein expression assays illustrated significant downregulation of GPX4 and depletion of intracellular glutathione pools post-treatment. Concurrently, quantitative PCR and Western blot analyses revealed enhanced NRF2 and HO-1 expression, signaling activation of adaptive oxidative stress responses.

Furthermore, live-cell imaging and biochemical assays documented mitochondrial depolarization and impaired oxidative phosphorylation capacity following drug exposure. Together, these insights underscore a coordinated disruption of cellular homeostatic networks, ultimately compromising survival and triggering ferroptotic pathways. This multidimensional disruption induced by Nelfinavir establishes a potent cytotoxic environment specifically detrimental to HCC cells.

The study also contextualizes the findings within the broader landscape of ferroptosis research, highlighting the growing recognition of ER stress as a pivotal initiator of ferroptotic signaling. ER stress sensors such as PERK and ATF4 respond to proteostatic imbalance by activating gene programs that intersect with antioxidant regulation and metabolic adaptations. Nelfinavir’s capacity to amplify this stress response effectively undermines cancer cells’ ability to marshal defensive responses.

Moreover, the precise mechanistic elucidation of how Nelfinavir modulates the GPX4/GSH system and NRF2/HO-1 axis enriches our understanding of ferroptosis’ regulatory complexity. It suggests that therapeutic strategies harnessing ER stress induction must consider the nuanced balance between pro-death and pro-survival pathways regulated by NRF2 and its downstream effectors. The data imply a threshold beyond which protective responses are insufficient, leading to ferroptosis execution.

Importantly, the investigation raises the tantalizing possibility that combining Nelfinavir with other agents targeting antioxidant defenses or mitochondrial function could potentiate ferroptosis induction, amplifying anti-tumor efficacy. Such combination therapies might overcome resistance mechanisms and achieve more durable responses in hepatocellular carcinoma. Future preclinical and clinical studies will be needed to explore these synergistic strategies.

The findings also underscore the value of drug repurposing in oncology, leveraging known safety profiles and pharmacodynamics of existing medications to accelerate innovative cancer therapies. Nelfinavir’s established clinical use provides a practical vantage point for rapid translation of ferroptosis-based interventions, potentially reducing development timelines and costs associated with novel drug discovery.

Beyond hepatocellular carcinoma, the mechanistic insights unveiled here may inform ferroptosis-targeted approaches across diverse malignancies exhibiting similar vulnerabilities in ER stress responses, redox regulation, and mitochondrial integrity. Such cross-cancer applicability further amplifies the significance of this research.

In sum, the study presents a comprehensive narrative detailing how Nelfinavir initiates ER stress, suppresses critical antioxidant systems, activates NRF2-mediated pathways, and disrupts mitochondrial function culminating in ferroptosis. This cascade offers an innovative therapeutic window for tackling hepatocellular carcinoma, addressing a critical unmet need. By illuminating these cellular mechanisms, the research breathes fresh life into ferroptosis exploration and exemplifies how integrative molecular pharmacology can revolutionize cancer treatment paradigms.

As the scientific community continues to unravel ferroptosis complexities, the potential to selectively eliminate resistant cancer cells through induced oxidative catastrophe is becoming an increasingly tantalizing reality. This investigation not only mirrors the evolving understanding of cell death modalities but also exemplifies the creative application of existing drugs toward novel anticancer strategies. The clinical horizon for hepatocellular carcinoma may soon be reshaped by such paradigm-shifting discoveries rooted in molecular precision and translational promise.

Subject of Research:
Hepatocellular carcinoma cell response to Nelfinavir-induced ferroptosis through ER stress mechanisms.

Article Title:
Nelfinavir triggers ferroptosis by inducing ER stress mediated downregulation of GPX4/GSH system, upregulation of NRF2/HO-1 axis, and mitochondrial impairment in hepatocellular carcinoma cells.

Article References:
Zhang, L., Wang, X. Nelfinavir triggers ferroptosis by inducing ER stress mediated downregulation of GPX4/GSH system, upregulation of NRF2/HO-1 axis, and mitochondrial impairment in hepatocellular carcinoma cells. Cell Death Discov. 11, 444 (2025). https://doi.org/10.1038/s41420-025-02761-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02761-w

NSCLC remains one of the deadliest forms of cancer worldwide, accounting for a significant proportion of lung cancer cases and deaths annually. Despite important advances with targeted therapeutics such as EGFR-TKIs, treatment efficacy is frequently thwarted by the tumor cells’ ability to develop drug resistance. Understanding the molecular underpinnings of such resistance is crucial for improving patient outcomes. Researchers Zeng, Wang, Qiao, and colleagues have addressed this gap by investigating how METTL16-dependent m6A modifications on GPX4 mRNA influence NSCLC cell behavior and drug responsiveness.

At the heart of this discovery lies the m6A RNA modification, an epitranscriptomic hallmark that regulates gene expression post-transcriptionally by dynamically altering RNA stability, translation, and splicing. METTL16, one of the relatively understudied methyltransferases responsible for catalyzing m6A modifications, has now been implicated in the pathological progression of NSCLC through its substrate, GPX4. GPX4, known for its pivotal role in detoxifying lipid peroxides, serves as a key regulator of ferroptosis—a form of regulated cell death driven by iron-dependent lipid peroxidation, distinct from apoptosis or necrosis.

Bioinformatic analyses of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets revealed a marked upregulation of METTL16 expression in NSCLC tissues compared to adjacent noncancerous counterparts. More significantly, elevated levels of METTL16 correlated adversely with patient prognosis, indicating its potential role as a prognostic biomarker. These findings set the stage for experimental validation, where overexpression studies in NSCLC cell lines such as PC9 and HCC827 demonstrated enhanced proliferation and marked resistance to AZD-9291.

Experimental mechanistic investigations employed methylated RNA immunoprecipitation (MeRIP) assays to pinpoint GPX4 mRNA as a direct target of METTL16-mediated m6A modification. This modification was shown to stabilize GPX4 transcripts, ultimately elevating GPX4 protein levels. The increase of GPX4 conferred an anti-ferroptotic phenotype to NSCLC cells, effectively sheltering them from ferroptosis triggered by oxidative stress and thus facilitating survival despite TKI treatment. Intriguingly, knockdown of METTL16 reversed this effect, restoring ferroptosis sensitivity and diminishing tumor cell proliferation.

The dual-luciferase reporter assays further elucidated the functional interaction between METTL16 and GPX4 mRNA, confirming that m6A modification enhanced GPX4 expression at the translational level. Rescue experiments underlined this regulatory axis: NSCLC cells with suppressed METTL16 and reduced GPX4 expression became significantly more susceptible to ferroptosis induction and exhibited reinstated responsiveness to AZD-9291 treatment, underscoring the therapeutic potential of targeting this pathway.

Ferroptosis, as a mode of cell death, has recently gained traction for its potential exploitation in cancer therapy. It operates through the accumulation of iron-dependent lipid peroxides, thereby compromising membrane integrity. The suppression of ferroptosis via upregulated GPX4 activity represents a cancer cell’s cunning survival strategy to evade TKI-induced cytotoxicity. This study reveals that METTL16’s m6A modification of GPX4 is a critical molecular lever by which NSCLC cells modulate ferroptosis to foster drug resistance.

These findings open several avenues for translational applications. Therapeutic interventions aimed at inhibiting METTL16 activity may serve to destabilize GPX4 mRNA, enhance ferroptosis, and resensitize resistant NSCLC tumors to TKIs such as AZD-9291. Moreover, this METTL16-GPX4 axis represents a promising biomarker for predicting patient responses and tailoring precision medicine approaches to overcome resistance.

Furthermore, the elucidation of m6A RNA modification mechanisms in cancer provides a broader understanding of epigenetic regulation beyond DNA methylation and histone modifications. As m6A writers, readers, and erasers continue to be characterized, their roles in oncogene regulation and cancer cell adaptation introduce a burgeoning field of potential targets for novel cancer therapeutics.

While much of the current clinical focus centers on blocking EGFR mutations directly with TKIs, the uncovering of epitranscriptomic contributors to resistance such as METTL16 urges the scientific and medical communities to consider combination strategies that target both genetic and epigenetic pathways. This dual-targeted approach might delay or prevent the emergence of resistance, extending patient survival and improving quality of life.

Importantly, the study employed rigorous methodologies, including Western blot analyses to quantify protein expression changes, and functional assays that monitor cell survival and proliferation under drug treatment, lending robust support to the proposed molecular mechanism. Such integrative use of in silico data mining and wet-lab confirmation exemplifies the state-of-the-art approach in cancer biology research today.

The implications extend beyond NSCLC, as ferroptosis resistance and m6A RNA modifications are increasingly recognized in diverse cancer types. Understanding the universality or tumor-specific aspects of METTL16-mediated GPX4 regulation may catalyze a new wave of research into overcoming drug resistance more broadly.

Critically, while targeting METTL16 appears promising, further studies are required to assess potential off-target effects or toxicities in normal tissues where m6A modifications also play fundamental roles. The balance between therapeutic efficacy and safety remains a cornerstone of drug development.

In conclusion, this landmark study uncovers a previously unrecognized epitranscriptomic pathway by which METTL16-mediated m6A modification of GPX4 mRNA inhibits ferroptosis, promoting proliferation and AZD-9291 resistance in NSCLC. These insights offer a compelling new target for overcoming TKI resistance, marking a significant advance in the understanding and potential treatment of one of the deadliest cancers.

Subject of Research: Molecular mechanisms underlying NSCLC resistance to tyrosine kinase inhibitors, focusing on METTL16-mediated m6A modification of GPX4 and its role in ferroptosis regulation.

Article Title: METTL16-dependent GPX4 m6A modification links ferroptosis to NSCLC TKIs resistance.

Article References:
Zeng, Y., Wang, Q., Qiao, D. et al. METTL16-dependent GPX4 m6A modification links ferroptosis to NSCLC TKIs resistance. BMC Cancer 25, 1335 (2025). https://doi.org/10.1186/s12885-025-14729-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14729-1